<?xml version='1.0' encoding='utf-8'?>
<document id="29955792"><sentence text="Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial."><entity charOffset="0-9" id="DDI-PubMed.29955792.s1.e0" text="Tucatinib" /></sentence><sentence text="Treatment options for patients with disease progression after treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1) are limited"><entity charOffset="90-100" id="DDI-PubMed.29955792.s2.e0" text="pertuzumab" /><entity charOffset="133-138" id="DDI-PubMed.29955792.s2.e1" text="T-DM1" /><pair ddi="false" e1="DDI-PubMed.29955792.s2.e0" e2="DDI-PubMed.29955792.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29955792.s2.e0" e2="DDI-PubMed.29955792.s2.e1" /></sentence><sentence text=" Tucatinib is an oral, potent, human epidermal growth factor receptor 2 (HER2)-specific tyrosine kinase inhibitor (TKI) being developed as a novel treatment for ERBB2/HER2-positive breast cancer"><entity charOffset="88-96" id="DDI-PubMed.29955792.s3.e0" text="tyrosine" /></sentence><sentence text="" /><sentence text="To determine the maximum tolerated dosage of tucatinib in combination with T-DM1 in the treatment of patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases"><entity charOffset="45-54" id="DDI-PubMed.29955792.s5.e0" text="tucatinib" /><entity charOffset="75-83" id="DDI-PubMed.29955792.s5.e1" text="T-DM1" /><pair ddi="false" e1="DDI-PubMed.29955792.s5.e0" e2="DDI-PubMed.29955792.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29955792.s5.e0" e2="DDI-PubMed.29955792.s5.e1" /></sentence><sentence text="" /><sentence text="In this phase 1b open-label, multicenter, clinical trial, 57 participants enrolled between January 22, 2014, and June 22, 2015, were 18 years of age or older with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane"><entity charOffset="250-256" id="DDI-PubMed.29955792.s7.e0" text="taxane" /></sentence><sentence text=" Data were analyzed between January and March 2018" /><sentence text="" /><sentence text="Tucatinib 300 mg or 350 mg administered orally twice per day for 21 days and T-DM1 3"><entity charOffset="77-82" id="DDI-PubMed.29955792.s10.e0" text="T-DM1" /></sentence><sentence text="6 mg/kg administered intravenously once every 21 days" /><sentence text="" /><sentence text="Safety assessments, pharmacokinetics, and response were assessed using RECIST 1" /><sentence text="1 every 2 cycles for 6 cycles, followed by every 3 cycles" /><sentence text="" /><sentence text="Fifty-seven T-DM1-naive patients (median [IQR] 51 [44"><entity charOffset="12-16" id="DDI-PubMed.29955792.s16.e0" text="T-DM1" /></sentence><sentence text="0-63" /><sentence text="0] years of age) who had undergone a median of 2 earlier HER2 therapies (range, 1-3) were treated" /><sentence text=" The tucatinib maximum tolerated dosage was determined to be 300 mg administered twice per day with dose-limiting toxic reactions seen at 350 mg twice per day" /><sentence text=" Pharmacokinetic analysis showed that there was no drug-drug interaction with T-DM1"><entity charOffset="78-82" id="DDI-PubMed.29955792.s20.e0" text="T-DM1" /></sentence><sentence text=" Adverse events seen among the 50 patients treated at the maximum tolerated dosage regardless of causality included nausea (36 patients; 72%), diarrhea (30 patients; 60%), fatigue (28 patients; 56%), epistaxis (22 patients; 44%), headache (22 patients; 44%), vomiting (21 patients; 42%), constipation (21 patients; 42%), and decreased appetite (20 patients; 40%); the majority of adverse events were grade 1 or 2" /><sentence text=" Tucatinib-related toxic reactions that were grade 3 and above included thrombocytopenia (7 patients; 14%) and hepatic transaminitis (6 patients; 12%)" /><sentence text="" /><sentence text="In this study, tucatinib in combination with T-DM1 appeared to have acceptable toxicity and to show preliminary antitumor activity among heavily pretreated patients with ERBB2/HER2-positive metastatic breast cancer with and without brain metastases"><entity charOffset="15-24" id="DDI-PubMed.29955792.s24.e0" text="tucatinib" /><entity charOffset="45-53" id="DDI-PubMed.29955792.s24.e1" text="T-DM1" /><pair ddi="false" e1="DDI-PubMed.29955792.s24.e0" e2="DDI-PubMed.29955792.s24.e0" /><pair ddi="false" e1="DDI-PubMed.29955792.s24.e0" e2="DDI-PubMed.29955792.s24.e1" /></sentence><sentence text="" /><sentence text="ClinicalTrials" /><sentence text="gov Identifier: NCT01983501" /><sentence text="" /></document>